Eugenio MarongiuGetty Images

Both bulking up and leaning down are admirable aims in isolation, and were willing to bet that you could do with a bit of both. But in practice, though, that can be a tall order after all, weight loss is achieved by cutting calories, which is the antithesis of getting swole. Fortunately, nutritionists at Skidmore College have discovered a workaround: a way to have your beefcake and eat it.

Their study pitted the standard eating plan of three meals a day (with 15% of your calories coming from protein, 60% from carbs and 25% from fat) against two high-protein diets, in which the protein ratio was doubled.

One group of high-protein dieters consumed their daily calorie intake over three main meals; the other ate six smaller meals.

Both high-protein groups lost more fat than those on the conventional eating plan, but the changes occurred much faster for those who doubled their meal count they were also the only group to gain lean mass over eight weeks.

The scientists attributed these results to a process called thermogenesis: eating little and often increased energy expenditure through digestion. Despite the calorie deficit, the steady supply of amino acids from the protein was also able to stop the subjects gains deflating. (Continued below)

This content is imported from YouTube. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

SUBSCRIBE

A dose every three hours proved to be optimal for protein synthesis, according to a separate study in Nutrition & Metabolism and so the six, high-protein meals a day were able to efficiently fuel gains in muscle alongside losses in weight.

Hungry for progress? Then chew on this new plan of action.

Sign up to the Men's Health newsletter and kickstart your home body plan. Make positive steps to become healthier and mentally strong with all the best fitness, muscle-building and nutrition advice delivered to your inbox.

SIGN UP

For effective home workouts, uplifting stories, easy recipes and advice you can trust, subscribe to Men's Health UK today

SUBSCRIBE

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

More:
Eat Little and Often: Nutritionists Find Eating More Could Aid Weight-Loss - Men's health UK

Healthline says: As you approach your goal weight and advance through these phases, your daily carb allowance increases, allowing you to incorporate a greater variety of foods.

The Atkins diet can help those wanting to reintroduce small amounts of carbohydrates back into their diet soon after starting it.

You can reintroduce 80-100 grams of carbs per day for ongoing weight maintenance.

The Keto diet involves reducing your total carb intake to less than 50 grams per day for the whole duration of your dieting.

The website says: While keto is a moderate-protein approach, with about 20% of calories coming from protein, the Atkins diet allows for up to 30 percent of calories from protein, depending on the phase.

Overall, Atkins is a less restrictive approach and may be more suitable for those wanting to try a diet first time.

Also you can eat a wider variety of foods such as more fruits and vegetables, which isnt usually allowed on the keto diet due to the amount of hidden carbs in these foods.

However both diets can help with weight loss and burning fat to reduce your overall body weight.

See original here:
Atkins vs Keto: The best diet for weight loss and to burn belly fat - Express

Whether you want to lose weight, get back in shape or simply become fitter and stronger, the weight loss journey of 38-year-old Dr Neha Gaur is bound to inspire you. After Neha gained a lot of weight post her second delivery, she started struggling with a host of health conditions. Her weight loss journey is an example that almost everything is possible in life, you just have to be dedicated enough! Read on. Name: Dr Neha Gaur Occupation: Physiotherapist & Certified fitness trainer

Age: 38 years Height: 5 feet 1 inch

City: GhaziabadHighest weight recorded: 73 kgWeight lost: 25 kgs

Duration it took me to lose weight: 7 months

The turning point: I had slowly gained a lot of weight post my second delivery in the year 2015 as I weighed 75 kilos. Along with all the extra kilos, I also started encountering a series of health issues including high thyroid levels and low vitamin D levels.

Gradually, my weight, the health issues I was suffering from along with my physical appearance, started impacting my mental health. I had reached a point where I started neglecting the nutritional needs of the body and resorted to all sorts of junk food. It was especially hard for me as I was a physical therapist as well as a fitness trainer and people had started judging my appearance and fitness levels.

I realised that it was high time and I needed to respect my body enough to take care of it. I started bringing in discipline in all aspects of my life, starting from January 2020 and results are here for everyone to see.

My breakfast: Wheat flakes, sugar-free muesli with low-fat milk along with a source of protein like egg whites, sprouts and moong dal cheela.

My lunch: I swear by portion control. My lunch included dal (pulses), vegetables, a big serving of salad, chapati, a portion of curd, a small portion of rice and something sweet at the end.

My dinner: I make sure I only eat proteins in my dinner and no carbs. So, I stick to vegetables and fruits.

Pre-workout meal: I choose between fruit, almonds, anjeer, prunes and roasted seeds. I have a cup of green tea or a black coffee along with my pre-workout meal.Post-workout meal: Protein shakeI indulge in: A cup of hot coffee with low-fat milk, cookies and home-cooked, lightly-fried meals.

My workout: I work out for 6 days a week for at least 1.5 hours every day. My workout routine consists of upper body and lower body exercises and core strengthening routines. I stick to HIIT twice a week and do power yoga once a week.

Low-calorie recipes I swear by: Bottle gourd steamed dumplings

Fitness secrets I unveiled: If you are on a journey to lose weight, get back in shape or even to reclaim your fitness levels, consistency with respect to your diet and workout routine is the most important step. Additionally, make sure to take proper rest and sleep well as they play a pivotal role in taking care of your mental and physical well being.

How do I stay motivated? When you start taking care of your body, you are bound to notice big and small changes in terms of your physical and mental strength. Also, the size of my clothes changed from XL to S, which also keeps me committed to this journey.

How do you ensure you dont lose focus? I make sure to monitor my weight regularly as it helps me to track my weight loss journey and stay focused. Also, the reactions from the people around lift my spirits and ensure that I continue giving 100 per cent efforts.

Read more here:
Lockdown weight loss story: 'I lost 25 kilos during the last 7 months with the help of a disciplined life - Times of India

Created for Greatist by the experts at Healthline. Read more

You probably dont need much of an explanation of what fasting is. But when it comes to how it could be good for you, well, that part might be a little less clear.

Fasting involves not taking in any calories for a specific period of time. Some religious fasting practices may require not consuming any food or beverage at all, regardless of calories.

The period might be as short as 12 hours, in the case of intermittent fasting. But traditional fasts, whether theyre for diet, cultural, or religious reasons, tend to be longer a day or more.

If youre assuming that giving your body an extended break from food might be helpful for weight loss, research suggests youre right on the money. But it turns out that fasting also has a bunch of other potential health benefits. Heres what the science has to say.

Fasting every other day has been found to be just as effective for weight loss as traditional low calorie diets. Aside from the fact that youll likely end up taking in fewer calories, going longer without eating seems to have a positive effect on blood sugar and fat burning. (More on that in a sec.)

And youll see results pretty quickly: A 2015 review concluded that whole-day fasts could help you shed up to 6 percent of your body fat in as little as 12 weeks.

However, the way you break your fast also matters. Returning to your pre-fasting ways (i.e., abandoning any lifestyle changes meant to maintain the weight loss) can result in weight regain.

As you fast, your body gradually relies more on fat than on carbs for energy, and your insulin production decreases.

Intermittent fasting can also do a bang-up job of reducing insulin resistance. That, in turn, can help make your body more sensitive to insulin, which translates into more stable blood sugar and fewer spikes and crashes.

While were talking about risk factors for heart disease, high cholesterol is another biggie. In a small 2010 study, fasting every other day slashed participants levels of LDL (bad) cholesterol and triglycerides by 25 and 32 percent, respectively.

In fact, long-term findings suggest that routine fasters are more than 70 percent less likely to have heart failure than folks who never fast.

Will fasting keep you from getting Alzheimers disease or experiencing cognitive decline? The jurys still out, but some research on mice suggests it could have a protective effect, in part because it fights inflammation.

Some may be concerned that fasting wont allow them to perform well in the gym or reap the full benefits of their exercise programs. But research has shown that people following intermittent fasting programs can still gain lean muscle, lose fat, and improve performance.

Full disclosure: Experts still have a lot to learn about the relationship between fasting and cancer. But animal studies suggest that periodic fasting might have an anticancer effect, meaning that the practice could play a role in cancer prevention.

The research also seems to suggest that fasting could make cancer treatments like chemotherapy more effective.

Fasting seems to help cells repair themselves, which might be why its tied to a lower risk of many diseases. Fasting could reduce the risk of several metabolic and cardiovascular conditions and having better overall health and less likelihood of illness could contribute to a longer life.

So, will limiting your food intake help you see 100? No guarantees, of course, but back in 1982, a study looking at rats found that rodents who fasted every other day aged at a slower rate and lived a whopping 83 percent longer than rats who didnt fast.

Science suggests that fasting can have a number of big health benefits, including helping you lose weight, regulating your blood sugar, and keeping your body in better shape overall.

In short, there are lots of good reasons to give it a try. Just talk with your doctor first. Fasting can take different forms and can sometimes have negative side effects, so its worth figuring out what type of fasting plan will work best for you and how to avoid or minimize any possible downsides.

Read more:
9 Science-Backed Benefits of Fasting - Greatist

People usually resort to exercise and dieting to lose weight. There is no doubt that healthy and limited diet is necessary to reduce body fat. But along with this, your meal time is also an important part in weight loss.

Nutritionists believe that how much and when you eat to reduce obesity, along with that your eating time is equally important. Actually, most people do not take care of the right time to eat food. Due to this they take a long time to lose weight.

What does research say?

According to a research from Harvard University, how much healthy you eat does not matter much. If you do not eat at the right time, you may have a lot of trouble losing weight. Eating at the same time every day keeps the balance between meal time and circadian rhythms. If there is a difference between these two, your blood sugar level may increase by 18 percent of normal.

Also read: According to Ayurveda, this is the best time to eat fruits.

Breakfast

Breakfast is the most important part of our meal. Breakfast should be taken between 6 to 10 am to reduce weight. A diet rich in more protein should be taken. It reduces body fat and hunger throughout the day. Nutrition experts believe that people having breakfast in the early morning can lose 15 kg more weight than others.

Also read: The weight of this boy was reduced to 100 kg.

Mid-morning snack

This is not very necessary. It takes at least 4 hours for our body to digest and absorb food. Therefore, a mid-morning snack should be taken 2 to 4 hours after the breakfast. Eating at the same time keeps the stomach full for a long time and keeps the energy level till noon.

Lunch

Lunch should be tried before 3 pm. According to a study published in the American Journal of Clinical Nutrition, people who eat lunch on time each day have fewer obesity problems. Also, weight also decreases rapidly.

Also read: Eat these 4 things as soon as you wake up in the morning, metabolism will increase quickly and weight will decrease

Evening snack

Like a morning snack, you should have an afternoon snack 2 to 4 hours after lunch. You can avoid overeating by having a snack between meals. Eating small amounts of times is a better option. During this time, almonds, fruits or smoothies can be taken. Fruits and boiled vegetables also help in weight loss.

Dinner

Dinner should be taken before 7 pm to lose weight. Dinner should be extremely light. Research has found that people having dinner till 7 pm consume 244 calories less. Which helps them in weight loss. Apart from this, one should sleep 1 to 2 hours after dinner.

Originally posted here:
Weight Loss: If you eat inappropriate meals, youll by no means drop pounds, know the best time from breakfast to dinner - Pledge Times

Crooke told Parsons to write down everything she was eating and to review the journals with him, she said. He told her to keep their discussions private, just as he had done with other runners, because, he said, it would cause people to stress and worry and it would negatively affect the teams performance, Parsons said.

In the spring of 2012, Palmer spoke with the then outgoing athletic director John Biddiscombe and incoming athletic director Whalen about the culture on the track and cross-country team. While her weight had not been addressed by the coach, she felt responsible to speak up on behalf of her teammates, bringing their testimonials to the meeting.

She said they asked her what she wanted to change in her relationship with the coach. When Palmer said she was not concerned about her relationship with coach, the meeting came to a close.

If I was a better, faster runner maybe he would have had the fat talk with me and I could talk about my own experience, she said. I was trying to bring to light a cultural systemic problem. They werent hearing that.

When runners are told to drop weight, they can quickly and dangerously find themselves lacking the energy required to maintain their health, said Dr. Kathryn Ackerman, the director of the Female Athlete Program at Boston Childrens Hospital and an assistant professor at Harvard Medical School.

Dr. Ackerman pointed to Relative Energy Deficiency in Sports, a common syndrome in female runners marked by the loss of a period or missed periods, low bone density, disordered eating, and debilitating injuries.

People are not unidimensional, said Dr. Paula Quatromoni, an associate professor of nutrition and epidemiology at Boston University and an expert on the intersection of sports nutrition and eating disorders.

Read the original:
Fat Talks, an Investigation, and a Reckoning: How Collegiate Runners Forced Reform - The New York Times

Popcorn can be a healthy, weight-loss-friendly snack (so long as it isn't saturated in butter).

Image Credit: agrobacter/iStock/GettyImages

Avoiding bananas, beans and bread because of the keto diet or any other weight-loss fad you're following? If you're limiting carbs in this way, you might be taking the wrong dietary approach.

The trouble with "cutting carbs" to lose weight is that we're lumping all sources of carbohydrates into one group.

Beans and gummy bears are both carbs but are far from the same when it comes to their nutritional value. Same goes for a candy bar and a banana: Both are a source of carbohydrates but they offer up very different macro and micronutrients.

As it is, whole grains and fruit account for less than 10 percent of our diet, per a September 2019 paper published in the Journal of the American Medical Association (JAMA).

The question is, what's happening in the other 90 percent of our diet? A big chunk about 42 percent of the portion of our diet that's not devoted to whole grains and fruits is made up of low-quality carbs, such as sugary cereal and white bread. These are the sources of carbohydrates that we need to limit in our diets when it comes to our weight and overall health, not fruit and whole grains.

Here, good-for-you carbs that'll fill you up and deliver nutrients, along with carbs to avoid.

6 Carbs to Add When You're Trying to Lose Weight

Potatoes of all hues even white ones are a nutrient-dense source of good-for-you carbs.

Image Credit: paulrichstudio/iStock/GettyImages

This goes for all potatoes red skinned, purple, sweet and the regular ol' white potato. Yes, that one too.

When it comes to healthy potato options, sweet potatoes often overshadow white spuds because of their rich orange color, which is an indication of their beta-carotene content. White potatoes are well, white, which we often associate with meaning a lack of nutrients, in addition to our antiquated "must avoid all white carbs" line of thinking.

But all potatoes are a source of good-for-you carbohydrates.

For starters, they're nutrient-dense. A medium potato (with skin) has just 118 calories and one gram of sugar while providing 3 grams of protein, 27 grams of carbohydrates, 2.5 grams of fiber, 20 percent of the daily value (DV) of vitamin C, 24 percent DV of vitamin B6 and 11 percent DV of folate, according to the United States Department of Agriculture (USDA).

When it comes to weight loss, potatoes are unique from many other foods in that they contain resistant starch, per a February 2020 narrative review published in the Journal of the Academy of Nutrition and Dietetics. This specific type of fiber may decrease the number of calories we process and increase satiety, along with other health benefits. One trick is cooking and then cooling a potato, like with a potato salad. This increases the amount of resistant starch.

Oatmeal is one of the first things to go when you start following a low-carb/keto diet and this isn't just unnecessary, it can be counterproductive if you're trying to lose weight.

Like potatoes, oats also contain a unique compound called beta-glucan. A growing body of research indicates that beta-glucan suppresses our appetite and increases our satiety, as reported in a paper published in Appetite in August 2018. Researchers of the study compared the effects of breakfast with beta-glucan versus one without. The group filling up on beta-glucan in the a.m. felt fuller afterwards, compared to the other non-beta-glucan group.

This one always seems to surprise. Yes, popcorn is a healthy source of carbs it's even a whole grain.

But choose wisely. A serving (about 3 cups) of air-popped popcorn has just 92 calories and 1 gram of fat while providing 19 grams of carbs and 4 grams of fiber, per the USDA. But that same size serving of movie theater popcorn has 276 calories, 25 grams of fat, 15 grams of saturated fat, 13 grams of carb and 2 grams of fiber, according to the USDA. Keep in mind, a small order of movie popcorn has 735 calories (!).

This makes (air-popped) popcorn a healthy and weight-loss-friendly snack. Women consume about 420 calories of snacks per day and men consume about 585 calories, according to the USDA. When snacking accounts for nearly 30 percent of your total intake, it pays to make it count by noshing on healthier options.

Bread has been demonized by low-carb enthusiasts but it's important to keep in mind that all bread is not created equal there's bread that is whole-grain and then there's refined. Whole grain means the entire grain is intact, ensuring you're getting all of the fiber and nutrients. A refined grain has been stripped of at least one of its three parts, usually the bran and germ, which removes some of the fiber, vitamins, minerals and healthy fats.

When you lump all grains together while cutting out carbs, you're doing yourself a disservice, especially when it comes to weight loss. Whole grains, which definitely include whole-grain bread, may give a modest boost to your metabolism, per a March 2017 study published in the American Journal of Clinical Nutrition.

These delicious berries are packed with fiber, an important nutrient for weight loss.

Image Credit: Michelle Arnold / EyeEm/EyeEm/GettyImages

Raspberries are loaded with fiber, which is a key nutrient when it comes to losing weight. In fact, they're one of the fruits highest in fiber with 8 grams per cup, according to the USDA. The only fruits with more are guava, avocado and passion fruit. Just think, eating one cup of raspberries provides about one-third of your entire fiber intake for the day (for women). Men need 38 grams per day.

So often when we're trying to lose weight we focus on cutting out calories or cutting out carbs but an October 2019 study published in the Journal of Nutrition found this is likely the wrong approach.

Researchers put subjects on a number of calorie-restricted diets varying in macronutrients i.e., low-fat, high protein, low-carb, high-carb, etc. After six months, they concluded that fiber intake, regardless of the macronutrient and calorie intake, was the biggest factor when it came to promoting weight loss and adhering to a calorie-restricted diet.

We need to be eating more legumes, plain and simple.

The 2015-2020 Dietary Guidelines for Americans compared the recommended intake to what we're currently consuming as a nation and the gap is wide. We only need to consume about 1 to 2 cups per week (depending on your calorie intake), which is nominal, although most dietitians would likely argue that you could benefit from more.

When it comes to losing weight, it behooves you to add legumes to your plate. Legume eaters (those who consume a three-fourths cup per day) lost more weight than those who didn't eat legumes, regardless of whether the diets were geared towards weight loss, per a March 2016 analysis published in the American Journal of Clinical Nutrition that reviewed the data from about 20 studies.

3 Carbs to Limit if You're Trying to Lose Weight

Bread on its own doesn't cause weight gain. It's eating an excess of calories that leads to gaining pounds. But certain foods fill you up and satisfy you more effectively than others. Refined grains, like white bread, are not one of these foods.

While clinical trials have been inconclusive in determining the benefits of refined and whole grains when it comes to weight loss, studies that look at diets longer term, like five years, have found a correlation between greater whole grain consumption and a reduced BMI, as outlined in as outlined in a June 2019 study published in Nutrients.

2. Sugary Breakfast Cereals

A bowl of granola or other boxed breakfast cereals can easily be a sugar bomb.

Image Credit: serezniy/iStock/GettyImages

Sugary breakfast cereals aren't doing you any favors. Sure, saving the colorful sweet marshmallows to slurp up with your milk is tasty and all, but you'll likely feel hungry soon after.

We have a sugar problem in the U.S. We currently eat two to three times as much as we should, which could be trouble for our waistlines, per Johns Hopkins Medicine. And while foods like doughnuts, chocolate and soda are obvious sources of added sugars, there are others, like breakfast cereals that may go undetected. Look for cereals with less than 10 grams of sugar per serving.

No one food will make you gain weight. It's your diet as a whole that matters most. But if semolina (refined) pasta is part of your regular diet, leveling up by switching to a more nutrient-rich version will help you in the long run. Since this pasta is made from refined grains, it's processed more quickly by your body, which raises blood sugars more quickly and leaves you feeling hungry sooner.

Fortunately, while our options in the pasta aisle used to be limited, these days, we can choose from noodles made out of red lentils, chickpeas, black beans and even konjac (a starchy plant).

These whole grains and legumes are higher in fiber, which slows digestion and leaves you feeling fuller longer, and legume-based pasta specifically has more protein, the most satiating macronutrient, per a July 2016 paper published in Annual Reviews.

The rest is here:
Trying to Lose Weight? Here Are 6 Carbs to Enjoy and 3 to Avoid - LIVESTRONG.COM

So Fernando Tatis Jr. is hitting the ball all over the park driving all manner of pitches to the seats beyond left field and somehow launching a low slider the other way over the wall in right field. He shares the major league lead with eight home runs and has the second highest OPS (1.184) in the game.

And the Padres are gushing about how boring hes being.

The kid is just over there fielding his position without incident.

What hes been doing, the most impressive part of this is hes been playing defense, third baseman Manny Machado said. Thats a big part of why the other side of things are flowing with him. Hes getting used to playing good shortstop. When youre at shortstop, youre basically the quarterback of the infield. You have to be on point at all times. Once you do that defensively you become an all-around player. Weve been seeing that.

Newsletter

Go deeper inside the Padres

Get our free Padres Daily newsletter, free to your inbox every day of the season.

Enter Email Address

Sign Me Up

You may occasionally receive promotional content from the San Diego Union-Tribune.

For all his diving stops and spectacular throws and athletic tags, Tatis in his rookie season had a penchant to throw balls away, make ill-advised throws and not consistently complete plays on routine grounders. It was perhaps the only knock against him, but it was a significant one.

In 84 games last year, he committed 18 errors (fourth most among shortstops) and had negative-12 outs above average (ranked 28th at his position).

Most problematic and the biggest contributor to those poor numbers was that he ranked 28th among shortstops who played at least 500 innings by making just 95.6 percent of plays (219 of 229 chances) that were considered virtually certain to be made.

Tatis has made every routine play this year, made one questionable throw and been bailed out a couple times on throws hopped to first base.

Said Bobby Dickerson, the Padres exacting infield coach: Through a small portion of the season, absolutely, his clock has been great, hes staying diligent in his daily routines. Hes finding the importance of not giving his opponent anything extra.

The Padres hoped/believed Tatis would improve on the routine. There is a history of extremely talented shortstops gaining wisdom and control after initially coming into the majors like gunslingers.

But the 21-year-old Tatis actually making the adjustment so quickly is why there is rejoicing in the organization.

It comes with maturity, said Dickerson, who is in his first season with the Padres. It takes a little time. Hes advanced in that way. He knows the importance of it as far as what winning looks like. Its one thing to have all the ability in the world, but if you cant play your trade, its all for naught. Hes been a great pupil. Hes the one doing it.

There is a prescience about Tatis that belies his age, and his so quickly improving this facet of his game is considered another example. In several instances over the past 16-plus months Tatis has been in the majors, people have referred to the head start he got and the incomparable tutelage he received from a father who played 11 big-league seasons.

Hes another level, Dickerson said of his young pupil. Hes got all the physical ability, and hes been raised the right way in the game. A lot of times we get really talented players that havent been around the game. I think Im just reiterating some of the things his daddy has told him.

First baseman Eric Hosmer lost upwards of 15 pounds while unable to keep food and liquids down for more than a week with what he says is a still-undiagnosed gastrointestinal issue. He is back up a few pounds (to 207 or 208) and expects the rest of the weight (another 12 or so pounds) to come back quickly now that he is able to eat pretty normal.

He said after Mondays 2-1 win over the Dodgers, in which he drove in the winning run with a sixth-inning single, that he feels great and credited the athletic training staff and others for getting him back to near full health, including stocking his hotel room with extra food.

I have a lot of things to stop, as far as putting sauce on food and just being aware what Im putting in my body now, he said. Ive always done a good job of that, but even more now Ive got to stay on top of it. Its not fun being on the IL, not fun watching these games on TV, so Ill make sure Im on top of all that stuff.

For the second time this season, Tingler changed his lineup Monday after checking with Tommy Pham shortly before game time. The switch involved making Pham the designated hitter rather than playing left field, as initially planned. Jurickson Profar played left field for the first time with the Padres.

If its not perfect right now, we adjust off it, Tingler said. Pham wants to get out there and go. At the end of the day, sometimes I have to be the bad guy, and well have a DH day.

When asked if Phams occasional soreness could be contributing to his recent 3-for-26 run, Tingler was practically incredulous.

He is hitting the ball hard, Tingler said. If I had concerns, I cant reiterate enough, Tommy Pham is not one, not (even) at the very bottom of concerns. I mean this as super respectful to a lot of players Ive been around, Ive just never really seen somebody with his work ethic, drive and desire to master his craft. There is zero concerns. Im just excited. As soon as that adjustment is made and it clicks, look out.

Of the 17 outs Pham has made on balls he has put in play, eight have been struck at 97.1 mph or harder. Only one of his three hits in that span have been hard hits (considered to be 95 mph or harder).

See original here:
Padres notes: Tatis the boring shortstop; Hosmer's lost weight: Pham's hard hits - The San Diego Union-Tribune

Simon Cowell has totally overhauled his lifestyle in the past couple of years and as a result has dropped a massive four stone.

It's thought that due to this healthier lifestyle it will help the entertainment mogul recover more quickly following his fall from an electric bike where he broke his back and needed six hours of surgery.

The 60 year old is in hospital recovering and "doing fine" after the accident, where he was reportedly just 1cm away from damaging his spinal cord and "almost paralysed".

Simon has been living in Malibu with his girlfriend Lauren Silverman and doting on their son Eric during lockdown, which was where the accident happened, and revealed back in May that he had been sticking to his vegan diet to keep on top of his weight loss.

Get exclusive celebrity stories and fabulous photoshoots straight to your inbox with OK's daily newsletter . You can sign up at the top of the page.

While speaking to Terri Seymour on Extra the Britain's Got Talent judge explained: "I think I have dropped, since I started this diet a year ago, 60 pounds."

He said being in quarantine with his family has made sticking to his strict no-meat-or-dairy diet much easier, besides the occasional temptations brought on by his six year old son Eric, who loves to order in pizza.

"Im doing a bit of cooking. Im exercising. Funny enough, more during this time as well, sticking to the diet," he said.

"The only difficult thing is when Eric orders a pizza... Thats the number one thing I miss."

Simon decided to become a vegan and exercise more after he had a health scare when he fainted and fell down the stairs in 2017.

Speaking about a health condition which saw him hospitalised, he told Extra: I went to see this guy whos very well-known. And he said to me, after doing some blood work, You cant have red meat, dairy, sugar, bread or gluten.

And opening up to The Sun, he confirmed what his diet now consists of. A friend of mine, who is a doctor, recommended speaking to an expert, and I did it on a whim. Within 24 hours I changed my diet and Ive not looked back since. You feel better, you look better.

I cut out a lot of the stuff I shouldnt have been eating and that was primarily meat, dairy, wheat, sugar those were the four main things.

It was way easier than you may think. Like, I used to have yoghurt in the morning and I changed it to almond-milk yoghurts. I have almond milk in my tea.

I can eat certain fruits but not all fruits. You have to be careful because some fruit can have more sugar than a can of Coke.

Simon, who still smoked, added: "I could see the difference. Cutting out sugar made a massive difference. The first few weeks were difficult, but then I actually stopped craving sugar. I had also found a brilliant gluten-free beer, which helps."

One of the ways Simon has been keeping fit after his lifestyle transformation is exercising.

He told Amanda Holden during an episode of Britains Got Talent: Unseen Bits he had done 150 press ups before I come to work in about three goes, according to The Sun.

The father of one also likes bike rides and his fellow BGT judge Amanda revealed his secret to keeping trim during filming.

"Hes not a runner. Hes definitely not a runner. He hasnt had to run for a bus for a long time, has he?! He has weights.

"When we do Britains Got Talent we get allocated one of the loos in the theatre that we just get to use.

"He has these things, I dont know what you call them. Theyre sort of stuck to the floor and they have handles so he can do his own press ups on them And it works! His upper body is amazing."

When Simon first debuted his new slimline appearance rumours were rife that he had had turned to surgery to aid with weight loss.

However, Simon explicitly denied this when talking to Best magazine. He said: People have said, Oh, hes had a gastric band fitted - but I havent.

"If I had, I would admit to it. This diet is all about what you put into your body. Its not the Atkins diet or anything else.

A source told the Daily Mail following Simon's fall that he would likely be ready in a months' time to film America's Got Talent finale.

"He is actually healthier than he ever has been which is why he was trying out an electric bike in the first place. He is, at least, in great shape to recover from it."

After his health scare Simon made a big change in his life, snapping up two family homes instead of living in a bachelor pad, preferring his 19m Malibu beach home

"Sometimes we get a reminder that were not invincible and this was certainly mine. It was a huge shock.

He said previously: "They think I fainted because I had low blood pressure and so I have got to take good care of myself to sort that out.

"After all, I am a dad and have more responsibility than ever."

In lockdown doting dad Simon has been sticking to his fitness and healthy eating regime as well as sleeping outside with his son Eric.

"I was concerned how [Eric] was going to cope with all of this. He has been absolutely amazing. He is still able to do schoolwork, and now we are camping on the weekends in the garden."

See the article here:
Simon Cowell body transformation as his four stone weight loss likely to help his recovery from fall - OK! magazine

ANNAPOLIS Aug 12, 2020 (Thomson StreetEvents) -- Edited Transcript of Altimmune Inc earnings conference call or presentation Wednesday, August 12, 2020 at 12:30:00pm GMT

* M. Scot Roberts

Altimmune, Inc. - Chief Scientific Officer

Altimmune, Inc. - Chief Medical Officer

* Vipin K. Garg

Altimmune, Inc. - President, CEO & Director

Altimmune, Inc. - CFO & Principal Accounting Officer

Greetings, and welcome to the Altimmune, Inc. Second Quarter 2020 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ms. Monique Kosse, Investor Relations for Altimmune. You may begin.

Thank you, Melissa, and thank you, everyone, for participating in today's Q2 2020 Earnings Conference Call. Leading the call today will be Dr. Vipin Garg, Chief Executive Officer of Altimmune. Also participating on the call today is Will Brown, Chief Financial Officer; Scott Roberts, Chief Scientific Officer; and Scott Harris, Chief Medical Officer.

After the prepared remarks, we will open up the call for a question-and-answer session. A press release with the Q2 2020 financial results was issued last night and can be found on the Investors page of the company's website.

Before we begin, I would like to remind everyone that remarks about future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including those related to COVID-19 and its impact on our business operations, clinical trials and results of operations.

For a discussion of some of the risks and factors that could affect the company's future results, please see the risk factors and other cautionary statements contained in the company's filings with the Securities and Exchange Commission. I would also direct you to read the forward-looking statement disclaimer in our earnings release issued last night and now available on our website.

Any statements made on this conference call speak only as of today's date, Wednesday, August 12, 2020, and the company does not undertake any obligation to update any of these forward-looking statements to reflect events or circumstances that occur after or on today's date.

As a reminder, this conference call is being recorded and will be available for audio rebroadcast on Altimmune's website on http://www.altimmune.com.

With that, I will now turn the call over to Vipin Garg, Chief Executive Officer of Altimmune. Vipin, please go ahead.

Vipin K. Garg, Altimmune, Inc. - President, CEO & Director [3]

Thank you, Monique. Good morning, everyone, and thank you for joining us as we discuss our Q2 2020 financial results and corporate update.

Joining me on the call today is Will Brown, our Chief Financial Officer, who will review our Q2 financial results; as well as Scott Roberts, our Chief Scientific Officer; and Scott Harris, our Chief Medical Officer. After our discussion, we will open the call for Q&A.

The first half of 2020 has been transformational for Altimmune, and I'm very pleased with our progress to date. We have made significant strides towards developing 2 product candidates to address the COVID-19 pandemic, a highly differentiated intranasal vaccine and a novel immunomodulatory therapeutic candidate. We secured additional government funding and capitalized the company sufficiently to fully lean into the challenges that lie ahead of us.

Outside of COVID-19, we continue to push forward aggressively on our other product candidates. We have recently completed enrollment in our NasoShield anthrax vaccine trial, and we are on track to begin an ALT-801 first-in-human NASH trial in Q4. We also had a successful IND submission for our chronic hepatitis B therapeutic, HepTcell, that is slated for a Phase II trial to begin later this year. With these advancements, we are well poised to deliver shareholder value throughout 2020 and beyond.

With that backdrop, I would like to spend a few minutes on our areas of focus for the remainder of this year. First, we are focused on expeditiously moving AdCOVID towards an IND and a Phase I clinical trial in Q4. We look forward to building on AdCOVID's outstanding preclinical data by moving it into the clinic as quickly and safely as possible. We are pleased with robust mucosal and systemic immunity observed in preclinical studies conducted by our collaborators at the University of Alabama at Birmingham. We have simultaneously forged alliances with several manufacturing partners to secure clinical trial material and began that process in July.

As Scott Roberts, our CSO, will discuss momentarily, these activities are going well, and we remain on track to begin our Phase I clinical trial later this year.

Second, we continue to pursue non-dilutive funding for AdCOVID. As previously announced, we entered into a teaming agreement with DynPort Vaccine Company, or DVC, to pursue federal and nonprofit funding. DVC, a General Dynamics Information Technology company, has extensive experience in vaccine development and has been the prime contractor and systems integrator for many government projects. The partnership with DVC significantly expands Altimmune's capabilities to execute on government contact on government funding opportunities and accelerate the development of AdCOVID.

Third, we remain focused on executing the T-COVID trial and maintaining DoD support. During the second quarter, we announced not only that we had created a new program based on [respira-vac], our replication-deficient adenovirus 5 platform, but that the Department of Defense awarded Altimmune $4.7 million to fund the EPIC Trial, our Phase I/II clinical trial of T-COVID in the prevention of clinical worsening in COVID-19.

We are especially excited about this program as it represents a novel mechanism with tremendous promise, and we are one of the few therapeutics intended to stop the progression of early COVID-19 to severe disease and hospitalization. We are working very closely with our colleagues at the U.S. Army Medical Research & Development Command on this program. And as Scott Harris, our CMO, will more fully discuss, we look forward to enrolling our first patient imminently and delivering top line data readout from this trial in Q4 of this year.

I would now like to turn the call over to Scott Roberts, our CSO, who will fully update you on the progress we have made with AdCOVID; and then Scott Harris, who will discuss our clinical plans across our portfolio. Scott Roberts?

--------------------------------------------------------------------------------

M. Scot Roberts, Altimmune, Inc. - Chief Scientific Officer [4]

--------------------------------------------------------------------------------

Thank you, Vipin, and good morning.

We have made excellent progress toward our Phase I clinical trial of AdCOVID, a single-dose intranasal vaccine candidate for COVID-19. Earlier this year, we created different vaccine candidates based on our [respira-vac] replication-deficient adenovirus vaccine platform. Candidates expressing different portions of the viral spike protein were evaluated in a series of preclinical studies performed by our collaborators at the University of Alabama at Birmingham.

Based on those results, we selected the candidate that expressed the receptor-binding domain, or RBD, of this viral spike protein for clinical development. The RBD is essential for viral infection, and the great majority of neutralizing antibodies in convalescent sera are directed against the RBD, so it's clearly an important target for the immune system.

In our preclinical mouse studies, a single intranasal dose of AdCOVID stimulated strong serum antibody responses and high virus neutralizing titers. Importantly, AdCOVID also induced a very robust mucosal IgA antibody response in the respiratory tract. Mucosal IgA is a special type of immunity that is produced locally to provide local protection from infection. When stimulated in the respiratory tract, mucosal immunity offers a potential to not only block infection but also block transmission of the virus to others. By far, the most important way to induce a nasal IgA response is to administer the vaccine intranasally. Bear in mind that all of the vaccine candidates in advanced clinical testing are delivered by intramuscular injection. Not only is that method of dosing more complicated than intranasal dosing, it's also unlikely to elicit mucosal IgA immunity in the respiratory tract.

The presence of nasal IgA may be especially important for protection from COVID-19 because of 2 important considerations: one, the SARS-CoV-2 virus replicates well in the nasal cavity; and two, antibodies against the virus that are in your blood can't get into the nasal cavity very well. So in the absence of local mucosal IgA immunity, the nasal cavity may become a safe haven for the virus.

Over the next few weeks, we'll be reporting on the ability of AdCOVID to stimulate T cell immunity, a third type of immunity we expect to stimulate, in addition to the neutralizing antibody and mucosal IgA responses. Once we have the T cell data in hand, we plan to quickly publish the preclinical data, so we can share it with the scientific community.

Now having identified the vaccine candidate we are taking forward, we initiated a dual-track approach towards the manufacturing of AdCOVID. While moving quickly to provide clinical trial material to conduct our Phase I trial later this year, we will begin scaling the manufacturing process in parallel to meet the requirements of Phase III testing and commercial launch of AdCOVID. To accomplish these aggressive goals, we have established multiple alliances with key manufacturing partners that have deep experience in the manufacturing of viral vectors.

Notably, we are using the same manufacturing process for AdCOVID as for our other vaccine candidates, including our NasoShield intranasal anthrax vaccine that we are developing with BARDA; and NasoVAX, our intranasal influenza vaccine. Using the same manufacturing process allows us to manufacture quickly and with confidence.

Additionally, vaccine candidates based on our respira-vac platform have shown excellent stability at room temperature, potentially allowing for the distribution of AdCOVID without the refrigeration or freezing that is normally required for other vaccines, greatly simplifying getting the vaccine to those who need it.

With that, I will turn the call over to Scott Harris, who will provide a clinical update on our programs. Scott?

--------------------------------------------------------------------------------

Matthew Scott Harris, Altimmune, Inc. - Chief Medical Officer [5]

--------------------------------------------------------------------------------

Thank you, Scott, and good morning, everyone. Continuing with our -- with the AdCOVID program, we expect to file the IND and launch the Phase I clinical trial of AdCOVID in the fourth quarter of 2020. This trial will include approximately 120 subjects. And while our preclinical studies and clinical trial data from our other intranasal replication-deficient adeno 5 virus (sic) [adenovirus 5] vaccine trials have not suggested the role for a prime boost, we nonetheless plan to evaluate the effects of 1 and 2 doses of vaccine to confirm this hypothesis. Immunogenicity analyses will include total serum IgG, neutralizing antibodies, nasal, mucosal immunity and T cell responses. We anticipate the data readout for the trial in the fourth -- in the first quarter of 2021 and launch a Phase II trial on the heels of this readout.

Based on the preclinical findings discussed earlier and prior experience with our other intranasal vaccines, we expect potent responses in all aspects of immunity and for AdCOVID to be safe and well tolerated, with adverse events and reactogenicity events similar to placebo.

We also previously announced that we're awarded $4.7 million by the U.S. Army Medical Research & Development Command to fund the entire cost of conducting a clinical trial with T-COVID. This trial will be known as the EPIC Trial or the Efficacy and Safety of T-COVID in the Prevention of Clinical Worsening in COVID-19. We have completed all of the government contracting processes and institutional reviews, and clinical sites are now active with enrollment expected to commence imminently.

T-COVID is an immune modulator for pulmonary viral infections and is differentiated for most other COVID-19 therapeutics in development, as it is focused on non-hospitalized patients prior to the development of pulmonary dysfunction and the need for hospitalization. Because of the broad protection T-COVID could afford against a variety of other respiratory pathogens, we believe it could be used to defend against future strains of coronavirus or other pandemics. The data readout from this trial is expected in the fourth quarter of 2020. And if successful, we plan to initiate a Phase II/III trial early next year and commence discussions regarding emergency use authorization.

We recently announced that we completed enrollment in our Phase Ib trial of NasoShield for anthrax and expect data readout on target in the fourth quarter of 2020. If NasoShield is shown to be safe and effective, the remaining options of our $133.7 million contract with BARDA could be awarded to complete Phase II clinical testing and begin stockpiling of NasoShield in the strategic reserve.

We also remain on track with IND-enabling studies in manufacturing to commence dosing in our first-in-man clinical trial for ALT-801, our GLP-1/glucagon dual agonist for NASH, in Australia in the fourth quarter of this year. We expect to have a readout on body weight loss and reduction in liver fat toward the end of the first quarter of 2021. This will be a value-driving event for investors as it will place ALT-801 squarely in the forefront of NASH development. We expect ALT-801 to be better tolerated than similar therapies and achieve weight loss and improvement of liver fat in the Phase I trial without the need to dose titrate for GI intolerability, which has impacted the GLP-1 development space.

At the conclusion of this first-in-human trial, we plan to file an IND in the U.S. and initiate a 12-week trial in patients with nonalcoholic fatty liver disease. We expect a data readout on this trial in the third quarter of 2021 and a transition rapidly to a full Phase IIb biopsy-based trial based on NASH endpoints by the end of 2021. Pending the results of the first-in-human trial, we may also elect to initiate a separate program in the treatment of obesity.

We feel confident that the efficacy and pharmacokinetic profile of ALT-801 in preclinical studies will translate to improve weight loss and tolerability, with more potent effects on weight loss and reduction in NASH activity compared to other agents.

Finally, we successfully filed the IND for HepTcell, our chronic hepatitis B immunotherapeutic. The Phase II trial is designed to evaluate the antiviral activity of HepTcell in chronically infected patients as an -- and is an important milestone in our goal to develop a functional cure for this disease.

Depending on the patient population being treated, the immunotherapeutic mechanism of HepTcell is intended to work alone or in combination with the new antiviral therapeutics that are being developed for this disease. We expect to initiate enrollment in the fourth quarter of 2020, pending evaluation of the impact of the COVID-19 pandemic.

And with that, I'll turn things back over to Vipin Garg. Vipin?

--------------------------------------------------------------------------------

Vipin K. Garg, Altimmune, Inc. - President, CEO & Director [6]

--------------------------------------------------------------------------------

Thank you, Scott.

As you may have noticed from Dr. Harris' remarks, it is important for us to continue the development of our portfolio outside of COVID-19. In addition to developments with AdCOVID and T-COVID, we expect to have a data-rich time period over the next 12 months, with data readouts from NasoShield in our anthrax trial, ALT-801 with our NASH trials and the initiation of a chronic hepatitis B trial with HepTcell.

One of the key tenets of our philosophy is to have multiple shots on goal, and we look forward to sharing the results of these clinical trials as they become available.

With that, I'll turn the call over to Will Brown, our Chief Financial Officer, who will provide an update on our financials. Will?

--------------------------------------------------------------------------------

William Michael Brown, Altimmune, Inc. - CFO & Principal Accounting Officer [7]

--------------------------------------------------------------------------------

Thank you, Vipin, and good morning, everyone.

For today's call, I'll be providing an update regarding our second quarter financial results.

Our cash and short-term investments balance was $80 million at June 30 for an increase of $47 million since the first quarter. The increase is attributable to $31.3 million of warrant exercises and nearly $23 million from our aftermarket facility. Since quarter end, we've received an additional $9.6 million from the exercise of warrants and $2.5 million from ATM sales. Additionally, we closed a public offering for gross proceeds of $132.2 million. With these additional cash receipts, Altimmune has more than $200 million of cash and investments on hand and is well positioned to advance its pipeline for at least the next 2 years.

As Scott Roberts discussed, a major use of the cash will be on the scale-up of manufacturing for both AdCOVID and T-COVID to meet the demands of both those COVID-19 product candidate.

Turning to the income statement. Revenues for the second quarter were $720,000, which is a reduction of $900,000 compared to the second quarter of last year. Our revenue was lower year-over-year, considering the NasoShield clinical trial and preclinical work performed during 2019 compared to clinical trial startup activities only performed in 2020.

Research and development expenses were $23.8 million for 2020 compared to $6.2 million in the same period last year. The increase year-over-year of $13.6 million is primarily attributable to stock-based milestone payments associated with ALT-801. We carry a liability on our balance sheet for the fair market value of these noncash payments. And during this quarter, we recognized $11.9 million of expense for an increase in the fair market value of the liability due to an increase in our stock price and an increase in the probability of success. Also impacting the change are increases in spend for the development of AdCOVID and T-COVID in addition to a decrease in spend for NasoShield due to the cycle of product development.

Second quarter G&A expenses of $2.5 million is $300,000 higher than the second quarter of 2019 due to an increase in compensation, legal and professional costs. Our income tax benefit for the quarter was $1.6 million, which represents the second quarter portion of our 2020 net loss, which we expect to file a refund claim next year.

Finally, net loss attributed to common stockholders for the second quarter was $16.8 million compared to $3.4 million in the same period last year, with net loss per share equaling $0.94 in the second quarter of 2020 versus $0.26 per share for the second quarter 2019.

With that, I would like to now open the call for questions and answers. Operator?

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions) Our first question comes from the line of Yasmeen Rahimi with Piper Sandler.

--------------------------------------------------------------------------------

Yasmeen Rahimi, Piper Sandler & Co., Research Division - Director & Senior Research Analyst [2]

--------------------------------------------------------------------------------

Congrats on the continued progress. Two questions for you. The first question is, can you shed light on what type of preclinical data we should be seeing between now and initiation of the Phase I study maybe to the level of granularity that you can provide us?

And then the second question is for Vipin. Can you shed light on the manufacturing? Maybe what is left in order to kick off the Phase I study? Are you thinking about working and adding on multiple manufacturers and continuing growing that?

--------------------------------------------------------------------------------

Vipin K. Garg, Altimmune, Inc. - President, CEO & Director [3]

--------------------------------------------------------------------------------

Yes. Yasmeen, thank you for the question. I would let Scott Roberts first to answer your first question, and I'll take the second question. Scott?

--------------------------------------------------------------------------------

M. Scot Roberts, Altimmune, Inc. - Chief Scientific Officer [4]

--------------------------------------------------------------------------------

Yes. Yasmeen, thanks for that question. So as far as the preclinical data between now and the clinical trial, as I mentioned during the call, the most immediate will be the T cell data. This is activation of T cell responses that are able to kill infected cells and reduce the infection that way. And we expect to have those data here very shortly. We'll also be reporting at that time on additional neutralizing antibody data that we've obtained that we're looking forward to sharing.

Beyond that, there'll be a continued evaluation of the specific types of antibody responses, what are the epitopes that are being targeted by both T cells and B cells. And we'll be looking at challenge models of COVID-19 in both rodents and nonhuman primates.

So that's kind of the broad brushstrokes of where we're going with that, and we look forward to sharing that data as it becomes available.

--------------------------------------------------------------------------------

Vipin K. Garg, Altimmune, Inc. - President, CEO & Director [5]

--------------------------------------------------------------------------------

And Yasmeen, with regards to manufacturing. As far as Phase I is concerned, we are well on our way to manufacturing materials for Phase I, as we announced almost over a month ago now that we entered into a partnership with Vigene Biosciences, and we've been working with them for a while. So they have -- they're in the process of manufacturing the Phase I materials and actually Phase I and Phase II materials.

But in addition to our partnership with Vigene, we have entered into an agreement with another large manufacturer, international manufacturer and a third manufacturer. We have not announced the names of these 2 manufacturing partners, but we are well on our way to securing sufficient manufacturing capacity for Phase III and beyond into commercialization of AdCOVID.

--------------------------------------------------------------------------------

Yasmeen Rahimi, Piper Sandler & Co., Research Division - Director & Senior Research Analyst [6]

Read more from the original source:
Edited Transcript of PIP earnings conference call or presentation 12-Aug-20 12:30pm GMT - Yahoo Finance